S65487 and azacitidine

Phase 1Small molecule

Institut de Recherches Internationales Servier

S65487 and azacitidine is one of 76 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

15 2

Vanflyta

Daiichi Sankyo

Phase 3

13 3

Busulfex

Akero Therapeutics

Phase 3

22 4

Trisenox

CCephalon

Phase 3

7 5

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

4 6

Bicnu

MMelissa K Accordino

Phase 3

1 7

Standard Chemotherapy

Roche

Phase 3

1 8

Active Comparator

Moderna

Phase 3

1 9

AG-120

Institut de Recherches Internationales Servier

Phase 3

4 10

Oblimersen Sodium

NNational Cancer Institute (NCI)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Active, not recruiting· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1/2·NCT04742101·57 enrolled

Chronic Lymphocytic Leukemia1 trial

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Terminated· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1·NCT03755154·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for S65487 and azacitidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S65487 and azacitidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S65487 and azacitidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut de Recherches Internationales Servier company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Institut de Recherches Internationales Servier

S65487 and azacitidine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Chronic Lymphocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News